Ardelyx (ARDX) financial statements

Healthcare · Biotechnology · Market cap $791M

Ardelyx reported revenue of $407M in fiscal 2025, up 32.8% a year over 8 years.

Net income was -$62M.

Free cash flow was -$44M.

The diluted share count rose 501% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-0.200.20.40.62016201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Ardelyx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Revenue—$42M$3M$5M$8M$10M$52M$124M$334M$407M
Cost of revenue—$8M$466,000$600,000$145,000$1M$4M$18M$51M$40M
Gross profit—$34M$2M$5M$7M$9M$48M$107M$283M$368M
Research and development$94M$75M$69M$72M$65M$91M$35M$36M$52M$72M
Selling, general and admin$19M$23M$24M$24M$33M$72M$77M$134M$259M$337M
Operating income-$113M-$65M-$91M-$91M-$91M-$154M-$64M-$63M-$28M-$41M
Interest expense——$4M$6M$5M$5M$3M$5M$13M$20M
Pre-tax income-$112M-$63M-$91M-$95M-$94M-$158M-$67M-$66M-$39M-$61M
Income tax—$1M$4,000$303,000$2,000$4,000$8,000$547,000$266,000$969,000
Net income-$112M-$64M-$91M-$95M-$94M-$158M-$67M-$66M-$39M-$62M
EPS (diluted)-$2.80-$1.36-$1.62-$1.47-$1.05-$1.52-$0.42-$0.30-$0.17-$0.26
Diluted shares40M47M56M64M90M104M159M219M235M241M
Gross margin—80.0%82.1%88.6%98.1%90.1%92.1%85.7%84.8%90.3%
Operating margin—-155.0%-3488.6%-1728.1%-1199.0%-1528.6%-122.2%-50.8%-8.4%-10.1%
Net margin—-153.2%-3502.0%-1797.8%-1245.7%-1566.5%-128.9%-53.1%-11.7%-15.1%

Balance sheet

Fiscal years, from Ardelyx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Cash and short-term investments$201M$134M$168M$247M$186M$117M$124M$184M$250M$265M
Receivables————$0$502,000$8M$22M$58M$72M
Inventory—————$0$28M$49M$91M$123M
Total current assets$204M$150M$176M$252M$195M$134M$154M$246M$356M$382M
Property, plant and equipment$9M$8M$6M$3M$2M$2M$1M$1M$1M$2M
Total assets$213M$158M$183M$260M$202M$150M$190M$298M$436M$502M
Total current liabilities$19M$18M$18M$22M$28M$53M$66M$50M$78M$89M
Total liabilities$20M$19M$68M$73M$75M$67M$92M$131M$262M$335M
Shareholders' equity$193M$139M$116M$187M$126M$83M$98M$167M$173M$167M
Net debt-$75M-$75M-$79M-$181M-$91M-$40M-$96M-$21M-$65M-$68M

Cash flow

Fiscal years, from Ardelyx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Operating cash flow-$93M-$65M-$70M-$76M-$81M-$153M-$70M-$90M-$45M-$42M
Capital spending$5M$2M$311,000$325,000$324,000$2M$55,000$344,000$1M$1M
Free cash flow-$97M-$68M-$71M-$77M-$82M-$154M-$70M-$90M-$46M-$44M
Stock-based compensation$5M$10M$9M$10M$11M$12M$11M$14M$37M$49M
Net borrowing————-$125,000—————
Free cash flow margin—-160.8%-2707.5%-1454.4%-1079.9%-1529.3%-134.4%-72.4%-13.7%-10.8%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARDX.
Open ARDX in Investingly

Questions

What was Ardelyx's revenue in 2025?

$407M in fiscal 2025, from its 10-K filing.

How much free cash flow does Ardelyx generate?

-$44M in fiscal 2025 (operating cash flow minus capital spending).

From Ardelyx's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.